IO-108

IO-108 · Immune-Onc Therapeutics

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for IO-108, covering 2024-05-24 to 2024-06-04. Get the full timeline:

Most recent: Clinical Trial Update: First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors [Phase 1]

See pricing